期刊文献+

PPARγ配体罗格列酮和GW9662对3T3-L1脂肪细胞内脏脂肪素mRNA表达的影响 被引量:4

Effects of PPARγ ligands rosiglitazone and GW9662 on Visfatin mRNA expression in 3T3-L1 adipocytes
下载PDF
导出
摘要 目的观察PPARγ配体罗格列酮(ROS)和GW9662对3T3-L1脂肪细胞Visfatin mRNA表达的影响,探讨PPARγ与Visfatin的关系。方法以不同浓度ROS和GW9662于各时段处理3T3-L1脂肪细胞,用RT-PCR技术检测VisfatinmRNA的表达。结果1、10、100μmol/L ROS抑制3T3-L1脂肪细胞Visfatin mRNA表达。1、5、25μmol/L GW9662抑制3T3-L1脂肪细胞Visfatin mRNA表达。5μmol/L GW9662不能拮抗10μmol/L ROS对Visfatin mRNA的抑制作用。 Objective To observe the effects of PPARγ ligands rosiglitazone and GW9662 on Visfatin mRNA expression in 3T3-L1 adipocytes.Methods Rosiglitazone and GW9662 in different concentrations were added into the culture medium of differentiated adipocytes for various times.Visfatin mRNA expression was measured by semiquantitative RT-PCR technique.Results ① 1,10,100 μmol/L rosiglitazone suppressed the Visfatin mRNA expression in 3T3-L1 adipocytes.② 1,5,25 μmol/L GW9662 suppressed the Visfatin mRNA expression in 3T3-L1 adipocytes.③ 5 μmol/L GW9662 could not antagonize the suppression of 10 μmol/L rosiglitazone on Visfatin mRNA expression in 3T3-L1 adipocytes.Conclusion rosiglitazone may affect the Visfatin mRNA expression via PPARγ-independent pathways.
出处 《安徽医科大学学报》 CAS 北大核心 2008年第5期504-508,共5页 Acta Universitatis Medicinalis Anhui
关键词 噻唑烷二酮类 PPARΓ 胰岛素抗药性 thiazolidinediones PPAR gamma insulin resistance
  • 相关文献

参考文献14

  • 1Fukuhara A, Matsuda M, Nishizawa M,et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin [ J ]. Science ,2005,307 ( 5708 ) :426 - 30. 被引量:1
  • 2Chen M P, Chung F M, Chang D M, et al. Elevated plasma level of visfatin/Pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[ J ]. Clin Endoerinol Metab,2006,91 ( 1 ) :295 - 9. 被引量:1
  • 3Kralich S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3 adipocytes[J]. Am J Physiol Endocrinol Metab,2005,289(4) :586 -90. 被引量:1
  • 4Yin W H, Jen H L, Chen J W,et al. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus star in treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia[ J]. Diabetes Metab,2006,32(3 ) :229 -35. 被引量:1
  • 5Fasshauer M, Klein J, Neumann S, et al. Hormonal regulation of adiponectin gene expression in 3T3-LI adipocytes [ J ]. Biochem Biophys Res Commun,2002,290 ( 3 ) : 1084 - 9. 被引量:1
  • 6Choi K C, Ryu O H, Lee K W, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats [ J ]. Biochem Biophys Res Commun ,2005,336 ( 3 ) :747 - 53. 被引量:1
  • 7Hammarstedt A , Pihlajamaki J, Sopasakis V, et al. Visfatin is an adipokine but it is not regulated by thiazolidinediones[ J ]. Clin Endocrinol Metab,2006,91 ( 3 ) : 1181 - 4. 被引量:1
  • 8MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 333-L1 pre-adipocytes and adipocytes[J].Diabetes Obes Metab,2007,9 (4) :490 -7. 被引量:1
  • 9石敏,代芳,王长江,沈俊飞.吡格列酮和白细胞介素-6对3T3-L1脂肪细胞Visfatin mRNA表达的影响[J].安徽医科大学学报,2008,43(1):50-54. 被引量:2
  • 10Boden G, Cheung P, Mozzoli M,et al. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes[J]. Metabolism,2003,52(6) :753 -9. 被引量:1

二级参考文献45

  • 1叶小龙,王长江,林刚,曹永红,代芳.Visfatin在2型糖尿病患者腹部皮下和网膜脂肪组织中的表达及其与胰岛素抵抗的关系[J].安徽医科大学学报,2007,42(2):205-207. 被引量:17
  • 2Guan Y, Breyer MD. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.Minerva Urol Nefrol, 2002,54: 65 ~79. 被引量:1
  • 3Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int, 2001,60: 14~30. 被引量:1
  • 4Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcriptional control of cellular processes. Drug News and Perspective, 2002,15: 147 ~ 154. 被引量:1
  • 5Desvergene B, Wahli W. Peroxisome proliferator-activated receptor: nuclear control of metabolism. Endocr Rev, 1999,20: 649 ~ 688. 被引量:1
  • 6Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic.Circulation, 2003,108: 1552~ 1553. 被引量:1
  • 7Koh EH, Kim MS, Park JY, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats:comparison with PPAR-gamma activation. Diabetes,2003, 52: 2331 ~2337. 被引量:1
  • 8Diep QN,Touyz RM, Schiffrin EL. Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension,2000,36: 851 ~855. 被引量:1
  • 9Duez H, Chao YS,Hernandez M,et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor-alpha agonist feofibrate in mice. J Biol Chem, 2002,277 :48051 ~ 48057. 被引量:1
  • 10Matsusue K, Peters JM, Gonzalez FJ. PPARβ/δ potentiates PPARγ-stimulates adipocyte differentiation. FASEB J, 2004Sep, 18: 1477 ~ 1479. Epub, 2004 Jul. 09. 被引量:1

共引文献52

同被引文献35

  • 1伍月红,冯崇廉.自拟疏肝消脂汤治疗脂肪肝的临床疗效分析[J].现代中西医结合杂志,2005,14(12):1601-1602. 被引量:9
  • 2Revollo J R,Korner A,Mills K F,Satoh A,Wang T,Garten A,et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metab, 2007,6:363-375. 被引量:1
  • 3Chen M P,Chung F M,Chang D M,Tsai J C,Huang H F,Shin S J, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab, 2006,91,295-299. 被引量:1
  • 4Haider D G, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin[J]. Diabetologia, 2006,49 : 1909-1914. 被引量:1
  • 5Chan T F,Chen Y L,Lee C H,Chou F H,Wu L C,Jong S B,et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus[J]. J Soc Gynecol Investig, 2006,13 : 364-367. 被引量:1
  • 6Li L,Yang G,Li Q, Tang Y,Yang M,Yang H,et al. Changes and relations of circulating visfatin,apelin, and resistin levels in normal,impaired glucose tolerance, and type 2 diabetic subjects [J]. Exp Clin Endocrinol Diabetes, 2006,114 : 544-548. 被引量:1
  • 7Dogru T,Sonmez A,Tasci I,Bozoglu E,Yilmaz M I,Genc H,et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance[J]. Diabetes Res Clin Pract, 2007,76 : 24-29. 被引量:1
  • 8Haider D G, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding[J].J Clin Endocrinol Metab,2006,91l 1578-1581. 被引量:1
  • 9Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon M R,et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans[J]. Diabetes, 2005, 54: 2911- 2916. 被引量:1
  • 10Yin W H,Jen H L,Chen J W,Lin S J,Young M S. Differential effects of peroxisome proliferator activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia[J]. Diabetes Metab, 2006,32 : 229 -235. 被引量:1

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部